http://www.xenon-pharma.com
Xenon Pharmaceuticals Inc. Company Intro
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Industry
Healthcare
Xenon Pharmaceuticals Inc. Headquaters
200 - 3650 Gilmore Way
Burnaby,V5G 4W8
Canada
Xenon Pharmaceuticals Inc. Share price
17 May 2023 14:08 GMT
$41.12
0.0 (0.0 %)
Xenon Pharmaceuticals Inc. Market cap
$2.586 B
WMC RANKING
2023
Xenon Pharmaceuticals Inc. # 218
BiotechnologyLatest Xenon Pharmaceuticals Inc. News
30 Nov 2023
Xenon Pharmaceuticals Jumps 5% After Pricing $300 Mln ...
Shares of Xenon Pharmaceuticals Inc. (XENE) jumped over 5% on Thursday morning after pricing of $300 million offering. XENE is currently trading at $35.60,...
30 Nov 2023
Will Xenon Pharmaceuticals Inc (XENE) Stay at the Top of the ...
Xenon Pharmaceuticals Inc gets a 71 rank in the Healthcare sector. Healthcare is number 5 out of 11 sectors. Overall Score - 55. XENE has an Overall Score of 55...
30 Nov 2023
Form 8-K Xenon Pharmaceuticals For: Nov 29
XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in Its Charter). Canada. 001-36687. 98-0661854. (State or Other Jurisdiction. of Incorporation).
WMC Market Score
WMC Market to Revenue Score
Xenon Pharmaceuticals Inc. Market Financials
Revenue, Expenses, Profit
| Company | Currency | Revenue | Expense | Profit | Market Cap | WMC Sector Score |
| Xenon Pharmaceuticals Inc. | USD | $29,446 | $68,773 | $-36,092 | $25,860B | 218 |
| Regeneron Pharmaceuticals, Inc. | USD | $9,197,600 | $3,997,800 | $4,003,800 | $804,390B | 1 |
| Vertex Pharmaceuticals Incorporated | USD | $6,414,881 | $2,617,257 | $2,762,032 | $878,880B | 2 |
| Alexion Pharmaceuticals, Inc. | USD | $6,261,601 | $2,747,200 | $681,800 | $ | 3 |
| Incyte Corporation | USD | $2,702,913 | $2,048,306 | $478,480 | $144,340B | 4 |
Market Analytics
Company Search vs Top 4 Industry Competitors
Total Xenon Pharmaceuticals Inc. Social Followers vs Top 4 Industry Competitors
Xenon Pharmaceuticals Inc. Post vs Top 4 Industry Competitors
Xenon Pharmaceuticals Inc. Digital Footprint By Size vs Top 4 Industry Competitors
Xenon Pharmaceuticals Inc. Digital Footprint By Change Rate vs Top 4 Industry Competitors
Xenon Pharmaceuticals Inc. WMC Market Score Calculations
| Details | Revenue | Total Social Followers | Total Social Posts | Search Volume | Digital Footprint Size | Digital change (New Pages) | WMC Market Score |
| Xenon Pharmaceuticals Inc. | 0.32 | 0 | 0 | 0 | 0 | 0 | 0 |
| Regeneron Pharmaceuticals, Inc. | 100 | 25.50 | 16.15 | 28 | 0 | 0 | 29.94 |
| Vertex Pharmaceuticals Incorporated | 69.75 | 35.68 | 8.95 | 40 | 0 | 0 | 36.32 |
| Alexion Pharmaceuticals, Inc. | 68.08 | 100 | 100 | 32 | 0 | 0 | 100 |
| Incyte Corporation | 29.39 | 5.03 | 0.04 | 100 | 0 | 0 | 45.31 |
Book a demo
Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.
* required fields
You'll learn how to:
- 1. Automatically monitor your entire digital landscape including competitors
- 2. View all new industry activity in real time
- 3. Monitor your position in your industry
- 4. Enrich your reports and strategy
- 5. Empower your teams with knowledge
